[Disclosure] Samsung Biologics (207940) – Outlook on Business Performance (Consolidated Financial Results) / 2024-01-24
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued its consolidated revenue guidance of KRW 4.16T for FY2024, which represents the midpoint of its projected YoY growth range (+10% to +15%). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Actual Revenue Achievement and Potential…